Evidence map›Paper›PMID 34732748›Full record

ArticleScientific reports2021

Sensitization of the UPR by loss of PPP1R15A promotes fibrosis and senescence in IPF.

Susan Monkley, Catherine Overed-Sayer, Helen Parfrey, Doris Rassl, Damian Crowther, Leire Escudero-Ibarz, Nicola Davis, Alan Carruthers, Richard Berks, Marisa Coetzee and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Aging and lung diseases: Unraveling mechanisms and therapeutic targets.Chinese medical journal pulmonary and critical care medicine · 2025
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Single-cell resolution of human airway epithelial cells exposed to bronchiolitis obliterans-associated chemicals.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Susan MonkleyTranslational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Catherine Overed-SayerBioscience COPD/IPF, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Helen ParfreyCambridge Interstitial Lung Disease Service, Royal Papworth Hospital, Cambridge, UK.
Doris RasslRoyal Papworth Hospital, Cambridge, UK.
Damian CrowtherNeuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Leire Escudero-IbarzDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Nicola DavisBioscience COPD/IPF, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Alan CarruthersBioscience COPD/IPF, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Richard BerksBiological Services Group, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.
Marisa CoetzeeBabraham Institute, Cambridge, UK.
Ewa KolosionekBioscience COPD/IPF, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Maria KarlssonBioscience COPD/IPF, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Leia R GriffinBioscience COPD/IPF, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Maryam ClausenTranslational Genomics, Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Graham BelfieldTranslational Genomics, Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Cory M HogaboamCedars-Sinai Department of Medicine, Los Angeles, CA, 90048, USA.
Lynne A MurrayBioscience COPD/IPF, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. lynnemurray@hotmail.com.
AstraZeneca (United Kingdom) · GBAstraZeneca (Sweden) · SEBabraham Institute · GBCedars-Sinai Medical Center · USMRC Laboratory of Molecular Biology · GBPapworth Hospital · GBUniversity of Ulster · GB

Funding

Medical Research Council MC_U105184326
6 · The paper itself

Abstract

The unfolded protein response (UPR) is a direct consequence of cellular endoplasmic reticulum (ER) stress and a key disease driving mechanism in IPF. The resolution of the UPR is directed by PPP1R15A (GADD34) and leads to the restoration of normal ribosomal activity. While the role of PPP1R15A has been explored in lung epithelial cells, the role of this UPR resolving factor has yet to be explored in lung mesenchymal cells. The objective of the current study was to determine the expression and role of PPP1R15A in IPF fibroblasts and in a bleomycin-induced lung fibrosis model. A survey of IPF lung tissue revealed that PPP1R15A expression was markedly reduced. Targeting PPP1R15A in primary fibroblasts modulated TGF-β-induced fibroblast to myofibroblast differentiation and exacerbated pulmonary fibrosis in bleomycin-challenged mice. Interestingly, the loss of PPP1R15A appeared to promote lung fibroblast senescence. Taken together, our findings demonstrate the major role of PPP1R15A in the regulation of lung mesenchymal cells, and regulation of PPP1R15A may represent a novel therapeutic strategy in IPF.

Indexed as

Cellular SenescenceUnfolded Protein ResponseAgedAnimalsBleomycinCell DifferentiationCell ProliferationEndoplasmic Reticulum StressFemaleFibroblastsFibrosisGenotypeHumansIdiopathic Pulmonary FibrosisIndolesLung(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanolBleomycinIndolesMorpholinesnintedanibPPP1R15A protein, humanPpp1r15a protein, mouseProtein Phosphatase 1Transforming Growth Factor beta

Identifiers

PMID34732748
PMCPMC8566588
OpenAlexW3172606778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.